![Learn more about The Renal Drug Database]({"type":"image" , "src" : "/sda/112410/ARN_0571_RDD_728x90px.jpg"})
References
- Caldwell R. B., Bartoli M., Behzadian M. A., El Remessy A. E., Al Shabrawey M., Platt D. H., et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003; 19: 442–55
- Funatsu H., Yamashita H., Nakanishi Y., Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 2002; 86: 311–5
- Hogeboom van Buggenum I. M., Polak B. C., Reichert‐Thoen J. W., Vries‐Knoppert W. A., van Hinsbergh V. W., Tangelder G. J. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia 2002; 45: 203–9
- Chaturvedi N., Sjolie A. K., Stephenson J. M., Abrahamian H., Keipes M., Castellarin A., et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin‐Dependent Diabetes Mellitus. Lancet 1998; 351: 28–31
- Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317: 713–20
- Vincent L., Chen W., Hong L., Mirshahi F., Mishal Z., Mirshahi‐Khorassani T., et al. Inhibition of endothelial cell migration by cerivastatin, an HMG‐CoA reductase inhibitor: contribution to its anti‐angiogenic effect. FEBS Lett 2001; 495: 159–66
- Weis M., Heeschen C., Glassford A. J., Cooke J. P. Statins have biphasic effects on angiogenesis. Circulation 2002; 105: 739–45
- Dichtl W., Dulak J., Frick M., Alber H. F., Schwarzacher S. P., Ares M. P., et al. HMG‐CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003; 23: 58–63
- Sen K., Misra A., Kumar A., Pandey R. M. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 2002; 56: 1–11
- Gordon B., Chang S., Kavanagh M., Berrocal M., Yannuzzi L., Robertson C., et al. The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol 1991; 112: 385–91
- Isner J. M., Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 1999; 103: 1231–6
- Kalka C., Masuda H., Takahashi T., Gordon R., Tepper O., Gravereaux E., et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 2000; 86: 1198–202
- Maeda T., Kawane T., Horiuchi N. Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology 2003; 144: 681–92
- Zambarakji H. J., Nakazawa T., Connolly E., Lane A. M., Mallemadugula S., Kaplan M., et al. Dose‐dependent effect of pitavastatin on VEGF and angiogenesis in a mouse model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2006; 47: 2623–31
- Vasa M., Fichtlscherer S., Adler K., Aicher A., Martin H., Zeiher A. M., et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001; 103: 2885–90
![Subscribe to The Renal Drug Database.]({"type":"image" , "src" : "/sda/112412/ARN_0571_RDD_300x250px.jpg"})
![Subscribe to The Renal Drug Database.]({"type":"image" , "src" : "/sda/112411/ARN_0571_RDD_160x600px.jpg"})